-
公开(公告)号：US6147219A
公开(公告)日：2000-11-14
申请号：US411162
申请日：1999-10-01
申请人： Christopher Goodwin
发明人： Christopher Goodwin
IPC分类号： C07C233/18 , C07C233/36 , C07C335/20 , C07C335/26 , C07D277/68 , C07D277/82
CPC分类号： C07D277/68 , C07C233/18 , C07C233/36 , C07C335/20 , C07C335/26 , C07D277/82
摘要： There are described processes for the preparation of a compound of formula I ##STR1## and novel intermediates in the preparative process.
-
公开(公告)号：US6118024A
公开(公告)日：2000-09-12
申请号：US410067
申请日：1999-10-01
申请人： Christopher Goodwin
发明人： Christopher Goodwin
IPC分类号： C07C233/18 , C07C233/36 , C07C335/20 , C07C335/26 , C07D277/68 , C07D277/82 , C07C205/37
CPC分类号： C07D277/68 , C07C233/18 , C07C233/36 , C07C335/20 , C07C335/26 , C07D277/82
摘要： There are described processes for the preparation of a compound of formula I ##STR1## and novel intermediates in the preparative process.
摘要翻译： 描述了在制备过程中制备式I化合物和新型中间体的方法。
-
公开(公告)号：US12002558B2
公开(公告)日：2024-06-04
申请号：US17898115
申请日：2022-08-29
发明人： James Blasetto , Judy Firor , David Guiga , William Mongan , Robert Prybolsky , Richard L. Skelly
IPC分类号： G16H20/10 , A61K31/505 , G16H50/30
CPC分类号： G16H20/10 , A61K31/505 , G16H50/30
摘要： A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.
-
公开(公告)号：US11972844B2
公开(公告)日：2024-04-30
申请号：US17323138
申请日：2021-05-18
申请人： AstraZeneca UK Ltd.
发明人： James Blasetto , Judy Firor , David Guiga , William Mongan , Robert Prybolsky , Richard L. Skelly
摘要： Systems and methods are provided for over the counter statin delivery to a subject. Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.
-
115.发明授权公开(公告)号：US11817195B2
公开(公告)日：2023-11-14
申请号：US17938310
申请日：2022-10-05
发明人： Robert Peter Prybolsky , Judy Firor
摘要： A method is provided for lowering blood sugar in a subject in need thereof by administering a gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes empagliflozin, canagliflozin, and ertugliflozin. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20220406428A1
公开(公告)日：2022-12-22
申请号：US17752681
申请日：2022-05-24
发明人： Richard L. SKELLY , Judy Firor
摘要： A method is provided for treating erectile dysfunction in a subject in need thereof by administering a cGMP-specific phosphodiesterase 5 (PDE5) inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the PDE5 inhibitor pharmaceutical composition. In some embodiments, the PDE5 inhibitor pharmaceutical composition includes tadalafil or vardenafil.
-
公开(公告)号：US20170231988A1
公开(公告)日：2017-08-17
申请号：US15364607
申请日：2016-11-30
IPC分类号： A61K31/505 , A61K9/50 , A61K9/28 , A61K9/16
CPC分类号： A61K31/505 , A61K9/167 , A61K9/1676 , A61K9/1694 , A61K9/2086 , A61K9/209 , A61K9/2813 , A61K9/282 , A61K9/2866 , A61K9/2886 , A61K9/2893 , A61K9/501 , A61K9/5015 , A61K9/5042 , A61K9/5073 , A61K9/5078 , A61K31/155 , A61K31/455 , A61K31/616 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.
-
公开(公告)号：US09616028B2
公开(公告)日：2017-04-11
申请号：US14706077
申请日：2015-05-07
发明人： Admassu Abebe , Kyle Martin , Jatin M. Patel , Divyakant Desai , Peter Timmins
IPC分类号： A61K9/28 , A61K9/24 , A61K31/155 , A61K31/7004 , A61K31/7042 , A61K45/06 , A61K31/403 , A61K31/70 , A61K31/7034 , A61K9/20
CPC分类号： A61K9/209 , A61K9/2054 , A61K9/282 , A61K31/155 , A61K31/403 , A61K31/70 , A61K31/7004 , A61K31/7034 , A61K31/7042 , A61K45/06 , A61K2300/00
摘要： The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
-
公开(公告)号：US20140294959A1
公开(公告)日：2014-10-02
申请号：US14118746
申请日：2012-05-17
IPC分类号： A61K9/28 , A61K9/16 , A61K31/505
CPC分类号： A61K31/505 , A61K9/167 , A61K9/1676 , A61K9/1694 , A61K9/2086 , A61K9/209 , A61K9/2813 , A61K9/282 , A61K9/2866 , A61K9/2886 , A61K9/2893 , A61K9/501 , A61K9/5015 , A61K9/5042 , A61K9/5073 , A61K9/5078 , A61K31/155 , A61K31/455 , A61K31/616 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.
摘要翻译： 本发明涉及含有式（I）的瑞舒伐他汀钙的药物组合物及其制备方法。
-
公开(公告)号：US08614320B2
公开(公告)日：2013-12-24
申请号：US13523534
申请日：2012-06-14
申请人： Akio Matsushita , Mizuho Oda , Yasuhiro Kawachi , Jun-ichi Chika
发明人： Akio Matsushita , Mizuho Oda , Yasuhiro Kawachi , Jun-ichi Chika
IPC分类号： C07D239/36 , C07D239/42 , C07D239/22 , A61K31/505 , A61P3/06
CPC分类号： C07D239/22 , C07D239/30 , C07D239/34 , C07D239/36 , C07D239/42
摘要： A 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound of the formula (3): [R is a hydrocarbyl group], is prepared by the steps of: (I) reacting an isobutyrylacetate ester with 4-fluorobenzaldehyde and urea in the presence of a protonic compound and a metal salt; (II) oxidizing the reaction product of the step (I); (III) reacting the oxidation product of the step (II) with an organic sulfonyl halide or an organic sulfonyl anhydride; and (IV) reacting the reaction product of the step (III) with N-methyl-N-methanesulfonamide.
摘要翻译： 通过以下步骤制备式（3）的2-（N-甲基-N-甲磺酰基氨基）嘧啶化合物：[R是烃基]：（I）使异丁酰乙酸酯与4-氟苯甲醛和尿素反应 质子化合物和金属盐的存在; （II）氧化步骤（I）的反应产物; （III）使步骤（II）的氧化产物与有机磺酰卤或有机磺酰酐反应; 和（IV）使步骤（III）的反应产物与N-甲基-N-甲烷磺酰胺反应。
-
-
-
-
-
-
-
-
-
搜索结果
143 条记录 (耗时 0.025 秒)
